Hubbry Logo
Adaptive immune systemAdaptive immune systemMain
Open search
Adaptive immune system
Community hub
Adaptive immune system
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Adaptive immune system
Adaptive immune system
from Wikipedia
A scanning electron microscope image of a single human lymphocyte

The adaptive immune system (AIS), also known as the acquired immune system or specific immune system, is a subsystem of the immune system that is composed of specialized cells, organs, and processes that eliminate pathogens specifically. The acquired immune system is one of the two main immunity strategies found in vertebrates (the other being the innate immune system).

Like the innate system, the adaptive immune system includes both humoral immunity components and cell-mediated immunity components and destroys invading pathogens. Unlike the innate immune system, which is pre-programmed to react to common broad categories of pathogen, the adaptive immune system is highly specific to each particular pathogen the body has encountered.[1]

Adaptive immunity creates immunological memory after an initial response to a specific pathogen, and leads to an enhanced response to future encounters with that pathogen. Antibodies are a critical part of the adaptive immune system. Adaptive immunity can provide long-lasting protection, sometimes for the person's entire lifetime. For example, someone who recovers from measles is now protected against measles for their lifetime; in other cases it does not provide lifetime protection, as with chickenpox. This process of adaptive immunity is the basis of vaccination.

The cells that carry out the adaptive immune response are white blood cells known as lymphocytes. B cells and T cells, two different types of lymphocytes, carry out the main activities: antibody responses, and cell-mediated immune response. In antibody responses, B cells are activated to secrete antibodies, which are proteins also known as immunoglobulins. Antibodies travel through the bloodstream and bind to the foreign antigen causing it to inactivate, which does not allow the antigen to bind to the host.[2] Antigens are any substances that elicit the adaptive immune response. Sometimes the adaptive system is unable to distinguish harmful from harmless foreign molecules; the effects of this may be hayfever, asthma, or any other allergy.

In adaptive immunity, pathogen-specific receptors are "acquired" during the lifetime of the organism (whereas in innate immunity pathogen-specific receptors are already encoded in the genome). This acquired response is called "adaptive" because it prepares the body's immune system for future challenges (though it can actually also be maladaptive when it results in allergies or autoimmunity).

The system is highly adaptable because of two factors. First, somatic hypermutation is a process of accelerated random genetic mutations in the antibody-coding genes, which allows antibodies with novel specificity to be created. Second, V(D)J recombination randomly selects one variable (V), one diversity (D), and one joining (J) region for genetic recombination and discards the rest, which produces a highly unique combination of antigen-receptor gene segments in each lymphocyte. This mechanism allows a small number of genetic segments to generate a vast number of different antigen receptors, which are then uniquely expressed on each individual lymphocyte. Since the gene rearrangement leads to an irreversible change in the DNA of each cell, all progeny (offspring) of that cell inherit genes that encode the same receptor specificity, including the memory B cells and memory T cells that are the keys to long-lived specific immunity.

Naming

[edit]
Google Ngram of "acquired immunity " vs. "adaptive immunity". The peak for "adaptive" in the 1960s reflects its introduction to immunology by Robert A. Good and use by colleagues; the explosive increase in the 1990s was correlated with the use of the phrase "innate immunity".

The term "adaptive" was first used by Robert Good in reference to antibody responses in frogs as a synonym for "acquired immune response" in 1964. Good acknowledged he used the terms as synonyms but explained only that he preferred to use the term "adaptive". He might have been thinking of the then not implausible theory of antibody formation in which antibodies were plastic and could adapt themselves to the molecular shape of antigens, and/or to the concept of "adaptive enzymes" as described by Monod in bacteria, that is, enzymes whose expression could be induced by their substrates. The phrase was used almost exclusively by Good and his students and a few other immunologists working with marginal organisms until the 1990s when it became widely used in tandem with the term "innate immunity" which became a popular subject after the discovery of the Toll receptor system in Drosophila, a previously marginal organism for the study of immunology. The term "adaptive" as used in immunology is problematic as acquired immune responses can be both adaptive and maladaptive in the physiological sense. Indeed, both acquired and innate immune responses can be both adaptive and maladaptive in the evolutionary sense. Most textbooks today, following the early use by Janeway, use "adaptive" almost exclusively and noting in glossaries that the term is synonymous with "acquired".[citation needed]

The classic sense of "acquired immunity" came to mean, since Tonegawa's discovery, "antigen-specific immunity mediated by somatic gene rearrangements that create clone-defining antigen receptors". In the last decade, the term "adaptive" has been increasingly applied to another class of immune response not so-far associated with somatic gene rearrangements. These include expansion of natural killer (NK) cells with so-far unexplained specificity for antigens, expansion of NK cells expressing germ-line encoded receptors, and activation of other innate immune cells to an activated state that confers a short-term "immune memory". In this sense, "adaptive immunity" more closely resembles the concept of "activated state" or "heterostasis", thus returning in sense to the physiological sense of "adaptation" to environmental changes.[citation needed]

Functions

[edit]
Overview of the processes involved in the primary immune response

Acquired immunity is triggered in vertebrates when a pathogen evades the innate immune system and (1) generates a threshold level of antigen and (2) generates "stranger" or "danger" signals activating dendritic cells.[3]

The major functions of the acquired immune system include:[citation needed]

  • Recognition of specific "non-self" antigens in the presence of "self", during the process of antigen presentation.
  • Generation of responses that are tailored to maximally eliminate specific pathogens or pathogen-infected cells.
  • Development of immunological memory, in which pathogens are "remembered" through memory B cells and memory T cells.

In humans, it takes 4–7 days for the adaptive immune system to mount a significant response.[4]

Lymphocytes

[edit]

T and B lymphocytes are the cells of the adaptive immune system. The human body has about 2 trillion lymphocytes, which are 20–40% of white blood cells; their total mass is about the same as the brain or liver. The peripheral bloodstream contains only 2% of all circulating lymphocytes; the other 98% move within tissues and the lymphatic system, which includes the lymph nodes and spleen.[2] In humans, approximately 1–2% of the lymphocyte pool recirculates each hour to increase the opportunity for the cells to encounter the specific pathogen and antigen that they react to.[5]

B cells and T cells are derived from the same multipotent hematopoietic stem cells, and look identical to one another until after they are activated. B cells play a large role in the humoral immune response, whereas T cells are intimately involved in cell-mediated immune responses. In all vertebrates except Agnatha, B cells and T cells are produced by stem cells in the bone marrow.[6] T cell progenitors then migrate from the bone marrow to the thymus, where they develop further.

In an adult animal, the peripheral lymphoid organs contain a mixture of B and T cells in at least three stages of differentiation:[citation needed]

  • Naive B and naive T cells, which have left the bone marrow or thymus and entered the lymphatic system, but have yet to encounter their matching antigen
  • Effector cells that have been activated by their matching antigen, and are actively involved in eliminating a pathogen
  • Memory cells, the survivors of past infections

Antigen presentation

[edit]

Acquired immunity relies on the capacity of immune cells to distinguish between the body's own cells and unwanted invaders. The host's cells express "self" antigens. These antigens are different from those on the surface of bacteria or on the surface of virus-infected host cells ("non-self" or "foreign" antigens). The acquired immune response is triggered by recognizing foreign antigen in the cellular context of an activated dendritic cell.[citation needed]

With the exception of non-nucleated cells (including erythrocytes), all cells are capable of presenting antigen through the function of major histocompatibility complex (MHC) molecules.[6] Some cells are specially equipped to present antigen, and to prime naive T cells. Dendritic cells, B-cells, and macrophages are equipped with special "co-stimulatory" ligands recognized by co-stimulatory receptors on T cells, and are termed professional antigen-presenting cells (APCs).[citation needed]

Several T cells subgroups can be activated by professional APCs, and each type of T cell is specially equipped to deal with each unique toxin or microbial pathogen. The type of T cell activated, and the type of response generated, depends, in part, on the context in which the APC first encountered the antigen.[3]

Exogenous antigens

[edit]
Antigen presentation stimulates T cells to become either "cytotoxic" CD8+ cells or "helper" CD4+ cells.

Dendritic cells engulf exogenous pathogens, such as bacteria, parasites or toxins in the tissues and then migrate, via chemotactic signals, to the T cell-enriched lymph nodes. During migration, dendritic cells undergo a process of maturation in which they lose most of their ability to engulf other pathogens, and develop an ability to communicate with T-cells. The dendritic cell uses enzymes to chop the pathogen into smaller pieces, called antigens. In the lymph node, the dendritic cell displays these non-self antigens on its surface by coupling them to a receptor called the major histocompatibility complex, or MHC (also known in humans as human leukocyte antigen (HLA)). This MHC-antigen complex is recognized by T-cells passing through the lymph node. Exogenous antigens are usually displayed on MHC class II molecules, which activate CD4+T helper cells.[3]

Endogenous antigens

[edit]

Endogenous antigens are produced by intracellular bacteria and viruses replicating within a host cell. The host cell uses enzymes to digest virally associated proteins and displays these pieces on its surface to T-cells by coupling them to MHC. Endogenous antigens are typically displayed on MHC class I molecules, and activate CD8+ cytotoxic T-cells. With the exception of non-nucleated cells (including erythrocytes), MHC class I is expressed by all host cells.[3]

T lymphocytes

[edit]

CD8+ T lymphocytes and cytotoxicity

[edit]

Cytotoxic T cells (also known as TC, cytotoxic T-lymphocytes (CTLs), or killer T cells) are a sub-group of T cells that induce the death of cells that are infected with viruses (and other pathogens), or are otherwise damaged or dysfunctional.[3]

Naive cytotoxic T cells are activated when their T-cell receptor (TCR) strongly interacts with a peptide-bound MHC class I molecule. This affinity depends on the type and orientation of the antigen/MHC complex, and is what keeps the CTL and infected cell bound together.[3] Once activated, the CTL undergoes a process called clonal selection, in which it gains functions and divides rapidly to produce an army of "armed" effector cells. The activated CTL then travels throughout the body searching for cells that bear that unique MHC class I + peptide.[citation needed]

When exposed to these infected or dysfunctional somatic cells, effector CTLs release perforin and granulysin: cytotoxins that form pores in the target cell's plasma membrane, allowing ions and water to flow into the infected cell and causing it to burst or lyse. CTLs release granzyme, a serine protease encapsulated in a granule that enters cells via pores to induce apoptosis (cell death). To limit extensive tissue damage during an infection, CTL activation is tightly controlled and in general requires a very strong MHC/antigen activation signal, or additional activation signals provided by "helper" T-cells.[3]

On resolution of the infection, most effector cells die and phagocytes clear them away—but a few of these cells remain as memory cells.[6] On a later encounter with the same antigen, these memory cells quickly differentiate into effector cells, dramatically shortening the time required to mount an effective response.[citation needed]

Helper T-cells

[edit]
The T lymphocyte activation pathway. T cells contribute to immune defenses in two major ways: some direct and regulate immune responses; others directly attack infected or cancerous cells.[7]

CD4+ lymphocytes, also called "helper" T cells, are immune response mediators, and play an important role in establishing and maximizing the capabilities of the acquired immune response.[3] These cells have no cytotoxic or phagocytic activity; and cannot kill infected cells or clear pathogens, but, in essence "manage" the immune response, by directing other cells to perform these tasks.[citation needed]

Helper T cells express T cell receptors (TCR) that recognize antigen bound to Class II MHC molecules. The activation of a naive helper T-cell causes it to release cytokines, which influences the activity of many cell types, including the APC (Antigen-Presenting Cell) that activated it. Helper T-cells require a much milder activation stimulus than cytotoxic T cells. Helper T cells can provide extra signals that "help" activate cytotoxic cells.[6]

Th1 and Th2: helper T cell responses

[edit]

Classically, two types of effector CD4+ T helper cell responses can be induced by a professional APC, designated Th1 and Th2, each designed to eliminate different types of pathogens. The factors that dictate whether an infection triggers a Th1 or Th2 type response are not fully understood, but the response generated does play an important role in the clearance of different pathogens.[3]

The Th1 response is characterized by the production of Interferon-gamma, which activates the bactericidal activities of macrophages, and induces B cells to make opsonizing (marking for phagocytosis) and complement-fixing antibodies, and leads to cell-mediated immunity.[3] In general, Th1 responses are more effective against intracellular pathogens (viruses and bacteria that are inside host cells).

The Th2 response is characterized by the release of Interleukin 5, which induces eosinophils in the clearance of parasites.[8] Th2 also produce Interleukin 4, which facilitates B cell isotype switching.[3] In general, Th2 responses are more effective against extracellular bacteria, parasites including helminths and toxins.[3] Like cytotoxic T cells, most of the CD4+ helper cells die on resolution of infection, with a few remaining as CD4+ memory cells.

Increasingly, there is strong evidence from mouse and human-based scientific studies of a broader diversity in CD4+ effector T helper cell subsets.[9][10] Regulatory T (Treg) cells, have been identified as important negative regulators of adaptive immunity as they limit and suppress the immune system to control aberrant immune responses to self-antigens; an important mechanism in controlling the development of autoimmune diseases.[6] Follicular helper T (Tfh) cells are another distinct population of effector CD4+ T cells that develop from naive T cells post-antigen activation. Tfh cells are specialized in helping B cell humoral immunity as they are uniquely capable of migrating to follicular B cells in secondary lymphoid organs and provide them positive paracrine signals to enable the generation and recall production of high-quality affinity-matured antibodies. Similar to Tregs, Tfh cells also play a role in immunological tolerance as an abnormal expansion of Tfh cell numbers can lead to unrestricted autoreactive antibody production causing severe systemic autoimmune disorders.[11]

The relevance of CD4+ T helper cells is highlighted during an HIV infection. HIV is able to subvert the immune system by specifically attacking the CD4+ T cells, precisely the cells that could drive the clearance of the virus, but also the cells that drive immunity against all other pathogens encountered during an organism's lifetime.[6]

Gamma delta T cells

[edit]

Gamma delta T cells (γδ T cells) possess an alternative T cell receptor (TCR) as opposed to CD4+ and CD8+ αβ T cells and share characteristics of helper T cells, cytotoxic T cells and natural killer cells. Like other 'unconventional' T cell subsets bearing invariant TCRs, such as CD1d-restricted natural killer T cells, γδ T cells exhibit characteristics that place them at the border between innate and acquired immunity. On one hand, γδ T cells may be considered a component of adaptive immunity in that they rearrange TCR genes via V(D)J recombination, which also produces junctional diversity, and develop a memory phenotype. On the other hand, however, the various subsets may also be considered part of the innate immune system where a restricted TCR or NK receptors may be used as a pattern recognition receptor. For example, according to this paradigm, large numbers of Vγ9/Vδ2 T cells respond within hours to common molecules produced by microbes, and highly restricted intraepithelial Vδ1 T cells respond to stressed epithelial cells.[citation needed]

B lymphocytes and antibody production

[edit]
The B lymphocyte activation pathway. B cells function to protect the host by producing antibodies that identify and neutralize foreign objects like bacteria and viruses.[7]

B Cells are the major cells involved in the creation of antibodies that circulate in blood plasma and lymph, known as humoral immunity. Antibodies (also known as immunoglobulin, Ig), are large Y-shaped proteins used by the immune system to identify and neutralize foreign objects. In mammals, there are five types of antibody: IgA, IgD, IgE, IgG, and IgM, differing in biological properties; each has evolved to handle different kinds of antigens. Upon activation, B cells produce antibodies, each of which recognize a unique antigen, and neutralizing specific pathogens.[3]

Antigen and antibody binding would cause five different protective mechanisms:

  • Agglutination: Reduces number of infectious units to be dealt with
  • Activation of complement: Cause inflammation and cell lysis
  • Opsonization: Coating antigen with antibody enhances phagocytosis
  • Antibody-dependent cell-mediated cytotoxicity: Antibodies attached to target cell cause destruction by macrophages, eosinophils, and NK cells
  • Neutralization: Blocks adhesion of bacteria and viruses to mucosa

Like the T cell, B cells express a unique B cell receptor (BCR), in this case, a membrane-bound antibody molecule. All the BCR of any one clone of B cells recognizes and binds to only one particular antigen. A critical difference between B cells and T cells is how each cell "sees" an antigen. T cells recognize their cognate antigen in a processed form – as a peptide in the context of an MHC molecule,[3] whereas B cells recognize antigens in their native form.[3] Once a B cell encounters its cognate (or specific) antigen (and receives additional signals from a helper T cell (predominately Th2 type)), it further differentiates into an effector cell, known as a plasma cell.[3]

Plasma cells are short-lived cells (2–3 days) that secrete antibodies. These antibodies bind to antigens, making them easier targets for phagocytes, and trigger the complement cascade.[3] About 10% of plasma cells survive to become long-lived antigen-specific memory B cells.[3] Already primed to produce specific antibodies, these cells can be called upon to respond quickly if the same pathogen re-infects the host, while the host experiences few, if any, symptoms.

Alternative systems

[edit]

In jawless vertebrates

[edit]

Primitive jawless vertebrates, such as the lamprey and hagfish, have an adaptive immune system that shows 3 different cell lineages, each sharing a common origin with B cells, αβ T cells, and innate-like γΔ T cells.[12][13] Instead of the classical antibodies and T cell receptors, these animals possess a large array of molecules called variable lymphocyte receptors (VLRs for short) that, like the antigen receptors of jawed vertebrates, are produced from only a small number (one or two) of genes. These molecules are believed to bind pathogenic antigens in a similar way to antibodies, and with the same degree of specificity.[14]

In insects

[edit]

For a long time it was thought that insects and other invertebrates possess only innate immune system. However, in recent years some of the basic hallmarks of adaptive immunity have been discovered in insects. Those traits are immune memory and specificity. Although the hallmarks are present the mechanisms are different from those in vertebrates.

Immune memory in insects was discovered through the phenomenon of priming. When insects are exposed to non-lethal dose or heat killed bacteria they are able to develop a memory of that infection that allows them to withstand otherwise lethal dose of the same bacteria they were exposed to before.[15][16] Unlike in vertebrates, insects do not possess cells specific for adaptive immunity. Instead those mechanisms are mediated by hemocytes. Hemocytes function similarly to phagocytes and after priming they are able to more effectively recognize and engulf the pathogen.[17] It was also shown that it is possible to transfer the memory into offspring. For example, in honeybees if the queen is infected with bacteria then the newly born workers have enhanced abilities in fighting with the same bacteria.[18] Other experimental model based on red flour beetle also showed pathogen specific primed memory transfer into offspring from both mothers and fathers.[19]

Most commonly accepted theory of the specificity is based on Dscam gene. Dscam gene also known as Down syndrome cell adhesive molecule is a gene that contains 3 variable Ig domains. Those domains can be alternatively spliced reaching high numbers of variations.[20] It was shown that after exposure to different pathogens there are different splice forms of dscam produced. After the animals with different splice forms are exposed to the same pathogen only the individuals with the splice form specific for that pathogen survive.[20]

Other mechanisms supporting the specificity of insect immunity is RNA interference (RNAi). RNAi is a form of antiviral immunity with high specificity.[21] It has several different pathways that all end with the virus being unable to replicate. One of the pathways is siRNA in which long double stranded RNA is cut into pieces that serve as templates for protein complex Ago2-RISC that finds and degrades complementary RNA of the virus. MiRNA pathway in cytoplasm binds to Ago1-RISC complex and functions as a template for viral RNA degradation. Last one is piRNA where small RNA binds to the Piwi protein family and controls transposones and other mobile elements.[22] Despite the research the exact mechanisms responsible for immune priming and specificity in insects are not well described.

In bacteria

[edit]
Bacteria use CRISPR as part of their adaptive immune system to defend against bacteriophages.

CRISPR is a term in DNA research. It stands for clustered regularly-interspaced short palindromic repeats. These are part of the genetic code in prokaryotes: most bacteria and archaea have it. It is their defence against attack by viruses.[23] Its structure and function was discovered in the 21st century.[24][25][26]

CRISPR has a lot of short repeated sequences. These sequences are part of an adaptive immune system for prokaryotes. It allows them to remember and counter the bacteriophages which prey on them. They work as a kind of acquired immune system for bacteria.[27][28]

Immunological memory

[edit]

When B cells and T cells are activated some become memory B cells and some memory T cells. Throughout the lifetime of an animal these memory cells form a database of effective B and T lymphocytes. Upon interaction with a previously encountered antigen, the appropriate memory cells are selected and activated. In this manner, the second and subsequent exposures to an antigen produce a stronger and faster immune response. This is "adaptive" in the sense that the body's immune system prepares itself for future challenges, but is "maladaptive" of course if the receptors are autoimmune. Immunological memory can be in the form of either passive short-term memory or active long-term memory.[citation needed]

Passive memory

[edit]

Passive memory is usually short-term, lasting between a few days and several months. Newborn infants have had no prior exposure to microbes and are particularly vulnerable to infection. Several layers of passive protection are provided by the mother. In utero, maternal IgG is transported directly across the placenta, so that, at birth, human babies have high levels of antibodies, with the same range of antigen specificities as their mother.[3] Breast milk contains antibodies (mainly IgA) that are transferred to the gut of the infant, protecting against bacterial infections, until the newborn can synthesize its own antibodies.[3]

This is passive immunity because the fetus does not actually make any memory cells or antibodies: It only borrows them. Short-term passive immunity can also be transferred artificially from one individual to another via antibody-rich serum.[citation needed]

Active memory

[edit]

In general, active immunity is long-term and can be acquired by infection followed by B cell and T cell activation, or artificially acquired by vaccines, in a process called immunization.

Immunization

[edit]

Historically, infectious disease has been the leading cause of death in the human population. Over the last century, two important factors have been developed to combat their spread: sanitation and immunization.[6] Immunization (commonly referred to as vaccination) is the deliberate induction of an immune response, and represents the single most effective manipulation of the immune system that scientists have developed.[6] Immunizations are successful because they utilize the immune system's natural specificity as well as its inducibility.[citation needed]

The principle behind immunization is to introduce an antigen, derived from a disease-causing organism, that stimulates the immune system to develop protective immunity against that organism, but that does not itself cause the pathogenic effects of that organism. An antigen (short for antibody generator), is defined as any substance that binds to a specific antibody and elicits an adaptive immune response.[2]

Most viral vaccines are based on live attenuated viruses, whereas many bacterial vaccines are based on acellular components of microorganisms, including harmless toxin components.[2] Many antigens derived from acellular vaccines do not strongly induce an adaptive response, and most bacterial vaccines require the addition of adjuvants that activate the antigen-presenting cells of the innate immune system to enhance immunogenicity.[6]

Immunological diversity

[edit]
An antibody is made up of two heavy chains and two light chains. The unique variable region allows an antibody to recognize its matching antigen.[7]

Most large molecules, including virtually all proteins and many polysaccharides, can serve as antigens.[3] The parts of an antigen that interact with an antibody molecule or a lymphocyte receptor, are called epitopes, or antigenic determinants. Most antigens contain a variety of epitopes and can stimulate the production of antibodies, specific T cell responses, or both.[3] A very small proportion (less than 0.01%) of the total lymphocytes are able to bind to a particular antigen, which suggests that only a few cells respond to each antigen.[6]

For the acquired response to "remember" and eliminate a large number of pathogens the immune system must be able to distinguish between many different antigens,[2] and the receptors that recognize antigens must be produced in a huge variety of configurations, in essence one receptor (at least) for each different pathogen that might ever be encountered. Even in the absence of antigen stimulation, a human can produce more than 1 trillion different antibody molecules.[6] Millions of genes would be required to store the genetic information that produces these receptors, but, the entire human genome contains fewer than 25,000 genes.[29]

Myriad receptors are produced through a process known as clonal selection.[2][3] According to the clonal selection theory, at birth, an animal randomly generates a vast diversity of lymphocytes (each bearing a unique antigen receptor) from information encoded in a small family of genes. To generate each unique antigen receptor, these genes have undergone a process called V(D)J recombination, or combinatorial diversification, in which one gene segment recombines with other gene segments to form a single unique gene. This assembly process generates the enormous diversity of receptors and antibodies, before the body ever encounters antigens, and enables the immune system to respond to an almost unlimited diversity of antigens.[3] Throughout an animal's lifetime, lymphocytes that can react against the antigens an animal actually encounters are selected for action—directed against anything that expresses that antigen.[citation needed]

The innate and acquired portions of the immune system work together, not in spite of each other. The acquired arm, B, and T cells could not function without the innate system input. T cells are useless without antigen-presenting cells to activate them, and B cells are disabled without T cell help. On the other hand, the innate system would likely be overrun with pathogens without the specialized action of the adaptive immune response.

Acquired immunity during pregnancy

[edit]

The cornerstone of the immune system is the recognition of "self" versus "non-self". Therefore, the mechanisms that protect the human fetus (which is considered "non-self") from attack by the immune system, are particularly interesting. Although no comprehensive explanation has emerged to explain this mysterious, and often repeated, lack of rejection, two classical reasons may explain how the fetus is tolerated. The first is that the fetus occupies a portion of the body protected by a non-immunological barrier, the uterus, which the immune system does not routinely patrol.[3] The second is that the fetus itself may promote local immunosuppression in the mother, perhaps by a process of active nutrient depletion.[3] A more modern explanation for this induction of tolerance is that specific glycoproteins expressed in the uterus during pregnancy suppress the uterine immune response (see eu-FEDS).[citation needed]

During pregnancy in viviparous mammals (all mammals except Monotremes), endogenous retroviruses (ERVs) are activated and produced in high quantities during the implantation of the embryo. They are currently known to possess immunosuppressive properties, suggesting a role in protecting the embryo from its mother's immune system. Also, viral fusion proteins cause the formation of the placental syncytium[30] to limit exchange of migratory cells between the developing embryo and the body of the mother (something an epithelium cannot do sufficiently, as certain blood cells specialize to insert themselves between adjacent epithelial cells). The immunodepressive action was the initial normal behavior of the virus, similar to HIV. The fusion proteins were a way to spread the infection to other cells by simply merging them with the infected one (HIV does this too). It is believed that the ancestors of modern viviparous mammals evolved after an infection by this virus, enabling the fetus to survive the immune system of the mother.[31]

The human genome project found several thousand ERVs classified into 24 families.[32]

Immune network theory

[edit]

A theoretical framework explaining the workings of the acquired immune system is provided by immune network theory, based on interactions between idiotypes (unique molecular features of one clonotype, i.e. the unique set of antigenic determinants of the variable portion of an antibody) and 'anti-idiotypes' (antigen receptors that react with the idiotype as if it were a foreign antigen). This theory, which builds on the existing clonal selection hypothesis and since 1974 has been developed mainly by Niels Jerne and Geoffrey W. Hoffmann, is seen as being relevant to the understanding of the HIV pathogenesis and the search for an HIV vaccine.

Stimulation of adaptive immunity

[edit]

One of the most interesting developments in biomedical science during the past few decades has been elucidation of mechanisms mediating innate immunity. One set of innate immune mechanisms is humoral, such as complement activation. Another set comprises pattern recognition receptors such as toll-like receptors, which induce the production of interferons and other cytokines increasing resistance of cells such as monocytes to infections.[33] Cytokines produced during innate immune responses are among the activators of adaptive immune responses.[33] Antibodies exert additive or synergistic effects with mechanisms of innate immunity. Unstable HbS clusters Band-3, a major integral red cell protein;[34] antibodies recognize these clusters and accelerate their removal by phagocytic cells. Clustered Band 3 proteins with attached antibodies activate complement, and complement C3 fragments are opsonins recognized by the CR1 complement receptor on phagocytic cells.[35]

A population study has shown that the protective effect of the sickle-cell trait against falciparum malaria involves the augmentation of acquired as well as innate immune responses to the malaria parasite, illustrating the expected transition from innate to acquired immunity.[36]

Repeated malaria infections strengthen acquired immunity and broaden its effects against parasites expressing different surface antigens. By school age most children have developed efficacious adaptive immunity against malaria. These observations raise questions about mechanisms that favor the survival of most children in Africa while allowing some to develop potentially lethal infections.

In malaria, as in other infections,[33] innate immune responses lead into, and stimulate, adaptive immune responses. The genetic control of innate and acquired immunity is now a large and flourishing discipline.

Humoral and cell-mediated immune responses limit malaria parasite multiplication, and many cytokines contribute to the pathogenesis of malaria as well as to the resolution of infections.[37]

Evolution

[edit]

The acquired immune system, which has been best-studied in mammals, originated in jawed fish approximately 500 million years ago. Most of the molecules, cells, tissues, and associated mechanisms of this system of defense are found in cartilaginous fishes.[38] Lymphocyte receptors, Ig and TCR, are found in all jawed vertebrates. The most ancient Ig class, IgM, is membrane-bound and then secreted upon stimulation of cartilaginous fish B cells. Another isotype, shark IgW, is related to mammalian IgD. TCRs, both α/β and γ/δ, are found in all animals from gnathostomes to mammals. The organization of gene segments that undergo gene rearrangement differs in cartilaginous fishes, which have a cluster form as compared to the translocon form in bony fish to mammals. Like TCR and Ig, the MHC is found only in jawed vertebrates. Genes involved in antigen processing and presentation, as well as the class I and class II genes, are closely linked within the MHC of almost all studied species.[citation needed]

Lymphoid cells can be identified in some pre-vertebrate deuterostomes (i.e., sea urchins).[39] These bind antigen with pattern recognition receptors (PRRs) of the innate immune system. In jawless fishes, two subsets of lymphocytes use variable lymphocyte receptors (VLRs) for antigen binding.[40] Diversity is generated by a cytosine deaminase-mediated rearrangement of LRR-based DNA segments.[41] There is no evidence for the recombination-activating genes (RAGs) that rearrange Ig and TCR gene segments in jawed vertebrates.

The evolution of the AIS, based on Ig, TCR, and MHC molecules, is thought to have arisen from two major evolutionary events: the transfer of the RAG transposon (possibly of viral origin) and two whole genome duplications.[38] Though the molecules of the AIS are well-conserved, they are also rapidly evolving. Yet, a comparative approach finds that many features are quite uniform across taxa. All the major features of the AIS arose early and quickly. Jawless fishes have a different AIS that relies on gene rearrangement to generate diverse immune receptors with a functional dichotomy that parallels Ig and TCR molecules.[42] The innate immune system, which has an important role in AIS activation, is the most important defense system of invertebrates and plants.

Types of acquired immunity

[edit]

Immunity can be acquired either actively or passively. Immunity is acquired actively when a person is exposed to foreign substances and the immune system responds. Passive immunity is when antibodies are transferred from one host to another. Both actively acquired and passively acquired immunity can be obtained by natural or artificial means.

  • Naturally Acquired Active Immunity – when a person is naturally exposed to antigens, becomes ill, then recovers.
  • Naturally Acquired Passive Immunity – involves a natural transfer of antibodies from a mother to her infant. The antibodies cross the woman's placenta to the fetus. Antibodies can also be transferred through breast milk with the secretions of colostrum.
  • Artificially Acquired Active Immunity – is done by vaccination (introducing dead or weakened antigen to the host's cell).
  • Artificially Acquired Passive Immunity – This involves the introduction of antibodies rather than antigens to the human body. These antibodies are from an animal or person who is already immune to the disease.
Naturally acquired Artificially acquired
Active – Antigen enters the body naturally Active – Antigens are introduced in vaccines.
Passive – Antibodies pass from mother to fetus via placenta or infant via the mother's milk. Passive – Preformed antibodies in immune serum are introduced by injection.

See also

[edit]

Notes and references

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
The adaptive immune system is a subsystem of the that mounts targeted defenses against specific pathogens and foreign substances known as antigens, providing long-lasting protection through its capacity for immunological memory. Unlike the , which delivers rapid but non-specific responses to a broad range of threats, the adaptive immune system develops over several days upon first exposure and exhibits high specificity, diversity, and the ability to "remember" previous encounters for quicker subsequent reactions. This antigen-dependent mechanism is essential for eliminating infections that evade initial innate defenses and forms the foundation of strategies. Key components of the adaptive immune system include lymphocytes—primarily B cells and T cells—that circulate in the blood, , and lymphoid organs such as the , lymph nodes, and . B cells differentiate into plasma cells that secrete antibodies to neutralize extracellular pathogens, while T cells include helper T cells that coordinate responses, cytotoxic T cells that destroy infected cells, and regulatory T cells that maintain tolerance to self-antigens. Antigen-presenting cells, like dendritic cells and macrophages, bridge the innate and adaptive systems by processing and displaying antigens on (MHC) molecules to activate lymphocytes. The system's specificity arises from and hypermutation processes that generate billions of unique receptors on B and T cells, allowing recognition of virtually any foreign molecule while avoiding self-reactivity. Upon , clonal expansion occurs, where antigen-specific lymphocytes proliferate rapidly, leading to effector functions such as production () or direct cell killing (). Memory cells persist long-term, enabling lifelong immunity to certain diseases, though dysregulation can contribute to autoimmune disorders or immunodeficiencies.

Overview

Definition and characteristics

The adaptive immune system is a subsystem of the that provides targeted defense against pathogens by mounting specific responses to antigens, primarily through the actions of lymphocytes. Unlike the , which offers immediate but non-specific protection, the adaptive system develops tailored reactions that improve with exposure. This subsystem relies on the recognition of specific antigens to initiate protective mechanisms. Its defining characteristics include antigen specificity, which enables precise identification of invading agents such as viruses or ; diversity, allowing the generation of receptors capable of recognizing millions of different ; immunological memory, which confers long-term immunity and accelerates subsequent responses to the same ; and self/non-self recognition, which prevents attacks on the host's own tissues while targeting foreign entities. These features collectively ensure a highly effective, adaptable defense that evolves during an individual's lifetime. The terminology has evolved historically; early descriptions referred to it as "specific" or "acquired" immunity to highlight its pathogen-targeted nature and development through exposure, but the term "adaptive" gained prominence starting in , when Robert A. Good and colleagues used it to describe the system's developmental and phylogenetic adaptability in vertebrates like frogs. This modern usage underscores its capacity for learning and refinement beyond mere acquisition.

Functions and importance

The adaptive immune system plays a central role in defending against specific pathogens by recognizing and eliminating them through targeted responses, contrasting with the broader, faster action of the . It achieves this by detecting specific antigens on pathogens, leading to their precise neutralization or destruction, which amplifies the initial innate defenses to clear infections more effectively. This specificity allows the system to mount responses that are tailored to individual threats, such as viruses or , rather than relying on generalized mechanisms. A key function is ongoing for abnormal cells, including those infected by viruses or transformed into cancerous states, where the system identifies and eliminates threats that evade innate detection. For instance, it recognizes mutated proteins on tumor cells as foreign, enabling targeted elimination to prevent progression. Additionally, the establishment of immunological ensures long-term protection, with memory cells persisting after initial exposure to enable rapid reactivation upon re-encounter with the same . This memory formation is crucial for preventing reinfections, as seen in diseases like , where prior exposure confers lifelong immunity. The importance of the adaptive immune system extends to its role in vaccine efficacy, where mimics to generate responses without causing , thereby protecting populations from outbreaks. Quantitatively, while the innate response activates within hours, the requires 4–7 days for a primary response, involving clonal expansion of lymphocytes to amplify effector cells by orders of magnitude. Secondary responses, however, occur within 1–3 days due to pre-existing , highlighting its in sustained defense. Dysfunction in the adaptive immune system underscores its critical role in health; for example, targets and depletes key components, leading to profound and increased susceptibility to opportunistic infections and cancers. Conversely, overactivity can contribute to , where self-tissues are mistakenly attacked, as in or . Overall, its balance is essential for maintaining immune and preventing chronic diseases.

Cells Involved

Lymphocytes: T and B cells

Lymphocytes are the primary cellular effectors of the adaptive immune system, originating from hematopoietic stem cells in the . All lymphocytes begin as common lymphoid progenitors in the , where they differentiate into either T or B cell lineages. T lymphocytes, or T cells, migrate from the to the as early thymic progenitors, where they undergo maturation through stages involving gene rearrangement and selection processes to ensure self-tolerance and specificity. In contrast, B lymphocytes, or B cells, complete their maturation entirely within the , progressing through pro-B, pre-B, and immature B cell stages before becoming mature naive s. T cells are central to , coordinating responses against intracellular pathogens and abnormal cells by directly killing targets or activating other immune components through release. B cells, on the other hand, drive by producing antibodies that neutralize extracellular pathogens, mark them for destruction, or enhance . Both cell types achieve their specificity through diverse receptors generated via during development, enabling recognition of a vast array of antigens. The T cell receptor (TCR), a heterodimeric protein typically composed of α and β chains, is expressed on the surface of T cells and recognizes peptide antigens presented by major histocompatibility complex (MHC) molecules on cell surfaces. Similarly, the B cell receptor (BCR), an membrane-bound immunoglobulin (usually IgM or IgD), allows B cells to bind directly to soluble or surface-bound antigens without MHC restriction. These receptors, along with co-receptors like CD4 on helper T cells and CD8 on cytotoxic T cells, or CD19 and Igα/Igβ on B cells, facilitate signal transduction upon antigen engagement. Naive lymphocytes constantly recirculate between the blood, lymphoid tissues, and peripheral organs to surveil for antigens, a process essential for mounting rapid adaptive responses. T and B cells enter secondary lymphoid organs, such as lymph nodes and , via high endothelial venules, guided by adhesion molecules like and chemokines including CCL19, CCL21, and CXCL13. Upon exiting these sites, they return to circulation through lymphatic vessels, ensuring broad patrolling of the body while minimizing energy expenditure. This recirculation is tightly regulated, with naive cells expressing receptors like CCR7 and to home to specific lymphoid compartments.

Antigen-presenting cells

Antigen-presenting cells (APCs) serve as critical intermediaries that bridge the innate and adaptive arms of the by capturing, processing, and displaying antigens to lymphocytes, thereby initiating targeted adaptive responses. Professional APCs, which include dendritic cells, macrophages, and B cells, are specialized for this function due to their high expression of () class II molecules and ability to provide necessary costimulatory signals for effective T cell activation. In contrast, non-professional APCs, such as most other nucleated cells, primarily express and play a limited role in priming naive T cells, focusing instead on surveillance for endogenous threats. Dendritic cells (DCs) are the most potent professional APCs, excelling in the capture and of antigens from diverse sources, including pathogens and damaged tissues, to prime naive T cells in lymphoid organs. Macrophages, tissue-resident , act as professional APCs by engulfing cellular debris and microbes, contributing to both innate clearance and adaptive priming, particularly in inflammatory contexts. B cells function as professional APCs primarily for antigens recognized by their receptors, enabling them to internalize and present specific pathogens to helper T cells, which in turn supports . Antigen uptake by professional APCs occurs through specialized mechanisms tailored to the nature of the . allows macrophages and immature DCs to internalize large particulate antigens, such as or apoptotic cells, via pattern recognition receptors like Toll-like receptors. , including receptor-mediated and fluid-phase pathways, enables B cells and DCs to capture soluble antigens or immune complexes, facilitating targeted internalization for subsequent into peptides suitable for MHC loading. Following uptake, professional APCs perform an initial overview of antigen degradation in endosomal compartments, preserving peptides for surface while integrating environmental cues to modulate the . Full activation of naive T cells by APC-presented antigens requires not only antigen recognition but also costimulatory signals to prevent anergy and promote proliferation and differentiation. The B7 family molecules and on professional APCs bind to on T cells, delivering a key signal that stabilizes the and amplifies T cell responses. This interaction, upregulated upon APC maturation, ensures that only relevant s in the context of danger signals trigger adaptive immunity. To prime lymphocytes effectively, professional APCs, particularly DCs, migrate from peripheral tissues to draining lymph nodes where naive T cells reside. This migration is orchestrated by the CCR7 on maturing DCs, which responds to ligands CCL19 and CCL21 in lymphatic vessels, enabling transport and in structured lymphoid environments. Macrophages and B cells also traffic to lymph nodes or via lymphatic or blood routes, positioning antigens for interaction with circulating lymphocytes.

Antigen Processing and Presentation

Exogenous antigens

Exogenous antigens are extracellular molecules, such as bacterial toxins, viral proteins released outside infected cells, or components from extracellular pathogens like certain parasites, that enter antigen-presenting cells (APCs) from the external environment. These antigens are distinct from intracellular threats and are primarily handled through the endosomal-lysosomal pathway to generate immune responses against infections occurring outside host cells. The processing of exogenous antigens begins with their uptake by APCs, such as dendritic cells, macrophages, or B cells, via mechanisms like , , or . Once internalized, the antigens are delivered to early endosomes, where the acidic environment promotes fusion with lysosomes containing proteolytic enzymes, including cathepsins. This degradation breaks down the antigens into fragments, typically 13-25 long, which are then transported to specialized compartments (MIICs). In these compartments, the invariant chain (Ii) dissociates from nascent molecules, allowing the fragments to bind to the MHC II groove, facilitated by , which edits the complex for optimal stability. The resulting peptide-MHC II complexes are transported to the cell surface for presentation. Presentation of exogenous antigens via activates + helper T cells, which recognize the complexes through their T cell receptors, leading to T cell proliferation and release. This activation is essential for initiating , as the helper T cells provide signals to B cells for production and class switching against extracellular pathogens. For example, protein subunit vaccines, such as those containing purified viral surface proteins like the hepatitis B surface antigen, are processed exogenously by APCs to generate MHC class II-restricted responses that drive protective antibody-mediated immunity.

Endogenous antigens

Endogenous antigens are intracellular proteins generated within host cells, such as viral proteins produced during or aberrant proteins arising from tumors, which are processed and presented to alert the to internal threats. These antigens are primarily handled through the cytosolic pathway, distinguishing them from extracellular threats managed via endosomal routes. The processing of endogenous antigens begins in the , where proteins—often including defective ribosomal products (DRiPs) that constitute a major source of peptides—are ubiquitinated and degraded by the 26S into short peptides, typically 8-10 long. These peptides are then transported across the (ER) membrane by the transporter associated with (TAP), a heterodimeric ATP-binding cassette protein composed of TAP1 and TAP2 subunits, which selectively binds and translocates peptides with appropriate hydrophobic anchors. In the ER lumen, the peptides are loaded onto newly synthesized (MHC-I) molecules within the peptide-loading complex (PLC), which includes chaperones like tapasin, , and ERp57 to edit and stabilize high-affinity peptide-MHC-I complexes, ensuring stable presentation. The assembled peptide-MHC-I complexes are transported through the Golgi apparatus to the cell surface, where they are displayed on nearly all nucleated cells, enabling surveillance by circulating CD8+ T cells for signs of or . Unlike MHC class II presentation, which is largely restricted to professional antigen-presenting cells (APCs), MHC-I expression is ubiquitous, allowing direct detection of compromised cells without intermediary processing. A specialized mechanism, , enables professional APCs such as dendritic cells to process and present exogenous —including those that originated as endogenous in neighboring cells (e.g., via uptake of infected cell debris or apoptotic bodies)—on to prime naive + T cells in lymph nodes. This process involves proteasomal degradation in the of the APC after antigen uptake, followed by TAP-dependent loading, and is crucial for initiating adaptive responses against viruses or tumors that do not directly infect APCs.

T Cell Mediated Immunity

CD8+ cytotoxic T cells

CD8+ cytotoxic T cells, also known as cytotoxic T lymphocytes (CTLs), are a subset of T lymphocytes that play a central role in by directly eliminating infected, cancerous, or abnormal cells. These cells express the coreceptor, which stabilizes their interaction with class I (MHC I) molecules on target cells presenting endogenous antigens, such as viral peptides or tumor-associated antigens. Upon activation, CD8+ T cells differentiate into effector cells capable of inducing target cell through specialized cytotoxic mechanisms. Activation of naive + T cells occurs primarily in secondary lymphoid organs, where they encounter antigen-presenting cells, such as dendritic cells, displaying peptides on MHC I via the (TCR). This TCR-MHC I interaction provides signal 1, while costimulatory signals from on the T cell binding to / on the deliver signal 2, preventing anergy and promoting full activation. Cytokines like IL-12 further drive differentiation by activating transcription factors such as T-bet and Eomesodermin, which upregulate effector genes. In the context of endogenous , this process ensures precise recognition of intracellular threats. Following , naive + T cells undergo rapid clonal expansion and differentiate into short-lived effector cells, with a subset surviving to form long-lived cells. This differentiation is influenced by the strength and duration of antigenic stimulation, as well as cytokines like IL-2, IL-7, and IL-15; brief exposure (2-24 hours) commits cells to effector fates, while prolonged signals favor formation. Effector + T cells acquire cytotoxic capabilities, including expression of perforin and granzymes, while cells, such as central and effector subsets, persist in lymphoid tissues or peripheral sites, enabling faster recall responses upon re-exposure. The transition involves downregulation of inhibitory receptors and upregulation of survival molecules like those in the TNF receptor family. The primary effector functions of CD8+ T cells involve inducing in target cells through two main pathways. In the perforin-granzyme pathway, activated CTLs release perforin to form pores in the target , allowing granzymes to enter and activate , leading to DNA fragmentation and cell death. Alternatively, CD8+ T cells express (FasL), which binds Fas receptors on target cells, triggering the extrinsic pathway via death-inducing signaling complex formation and activation. These mechanisms are calcium-dependent for and ensure without widespread tissue damage. CD8+ T cells are essential for viral clearance by recognizing and lysing virus-infected cells expressing viral peptides on MHC I, as demonstrated in infections like and where their depletion leads to persistent . In tumor surveillance, they patrol tissues to detect and eliminate neoplastic cells displaying mutated or overexpressed antigens, with high CD8+ infiltration in "" tumors correlating with better and response to . Additionally, CD8+ T cells contribute to by mounting alloreactive responses against mismatched MHC I on donor tissues, driving acute graft destruction through effector infiltration and cytokine production like IFN-γ and TNF-α.

CD4+ helper T cells

CD4+ helper T cells, also known as CD4+ T cells, are activated when their (TCR) recognizes peptide antigens presented by class II (MHC II) molecules on antigen-presenting cells, such as dendritic cells, in the context of costimulatory signals like CD28 binding to CD80/CD86. This activation occurs primarily in response to exogenous antigens processed by professional antigen-presenting cells. Upon activation, naive CD4+ T cells proliferate and differentiate into distinct subsets based on the milieu, transcription factors, and environmental signals, enabling them to coordinate tailored adaptive immune responses. The major subsets include Th1, Th2, Th17, and regulatory T (Treg) cells, each characterized by unique cytokine profiles and functions. Th1 cells differentiate under the influence of IL-12 and IFN-γ, driven by the T-bet, and secrete IFN-γ and IL-2 to promote macrophage activation and against intracellular pathogens. Th2 cells arise in the presence of IL-4, regulated by GATA3, producing IL-4, IL-5, and IL-13 to support and defense against extracellular parasites, though they also contribute to allergic responses. Th17 cells develop via TGF-β, IL-6, IL-21, and IL-23, with RORγt as the master regulator, secreting IL-17A/F and IL-22 to recruit neutrophils and combat extracellular and fungi, but implicated in when dysregulated. Treg cells, induced by TGF-β and IL-2 under control, produce IL-10 and TGF-β to suppress excessive immune activity and maintain tolerance to self-antigens. Through secretion, + T cells orchestrate broader immune responses: Th1-derived IFN-γ activates macrophages for enhanced and promotes + T cell differentiation, while Th2 s like IL-4 drive class switching to IgE and recruitment. Th17 IL-17 induces proinflammatory to amplify innate responses, and Treg s dampen inflammation to prevent tissue damage. These helper functions are critical for activating s toward production and licensing + cytotoxic T cells for effective viral clearance. CD4+ T cells play pivotal roles in vaccine-induced immunity by providing help for long-lived antibody responses and formation, as seen in vaccines against viruses like and where robust CD4+ responses correlate with protection. In chronic infections, such as , sustained antigen exposure leads to CD4+ T cell exhaustion, marked by reduced production, upregulated inhibitory receptors like PD-1, and impaired proliferation, contributing to progression. Similarly, in cancer, exhausted CD4+ T cells fail to sustain antitumor immunity, allowing tumor evasion, though their partial retention of effector functions underscores potential therapeutic targets like checkpoint blockade.

Gamma delta T cells

Gamma delta (γδ) T cells represent a distinct subset of T lymphocytes characterized by their heterodimeric (TCR) composed of γ and δ chains, in contrast to the α and β chains found in conventional αβ T cells. This γδ TCR enables recognition of antigens in an MHC-independent manner, allowing γδ T cells to respond directly to stress signals or pathogen-associated molecules without requiring by (MHC) molecules on antigen-presenting cells. Unlike αβ T cells, which primarily mediate adaptive immunity through MHC-restricted recognition, γδ T cells bridge innate and adaptive responses by acting as rapid sentinels in peripheral tissues. A hallmark of γδ T cells is their ability to recognize non-peptide antigens, such as phosphoantigens produced by bacteria like or synthesized by host cells under stress. These small phosphorylated metabolites, including isopentenyl pyrophosphate (IPP), are detected via the γδ TCR in conjunction with butyrophilin family molecules like BTN3A1 and BTN2A1, particularly in the Vγ9Vδ2 subset predominant in human peripheral blood. This recognition mechanism facilitates swift activation without the need for classical , enabling γδ T cells to mount early defenses against intracellular pathogens and tumors. γδ T cells play critical roles in early immune responses to infections, where they rapidly produce pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17) to recruit neutrophils and promote clearance. In , subsets like murine Vγ6Vδ1 cells in the and lungs secrete IL-22 to support epithelial repair and tissue regeneration, while decidual γδ T cells in produce growth factors such as binding protein 2 (IGFBP2) and C (VEGFC) to aid development. For mucosal immunity, γδ T cells maintain barrier integrity at sites like the gut and by regulating composition—such as suppressing pathobionts like Aggregatibacter via IL-17—and defending against viruses, , and fungi through IFN-γ-mediated antiviral and antibacterial effects. These functions are supported by the tissue-resident nature of γδ T cells, which constitute 10-30% of T cells in the skin and up to 40% in the , guided by receptors like and CCR6 in the or BTNL1-BTNL6 and α4β7 in the gut. Upon , resident γδ T cells exhibit innate-like rapid production, releasing IFN-γ and IL-17 within hours to orchestrate immediate inflammatory responses before adaptive immunity fully engages. This positioning and responsiveness position γδ T cells as key effectors in frontline mucosal and epithelial defense.

B Cell Mediated Immunity

B cell activation

B cells are activated upon recognition of antigens by their (BCR), a membrane-bound immunoglobulin that binds native, soluble, or membrane-associated antigens with high specificity. This binding triggers BCR clustering and initiates intracellular signaling cascades involving kinases such as Syk and Src family members, leading to the internalization of the antigen-BCR complex via clathrin-dependent . The internalized antigen is then processed into peptides within endosomal compartments and loaded onto major histocompatibility complex class II (MHC II) molecules for presentation on the B cell surface. In the T-dependent activation pathway, antigen-activated B cells migrate to the T cell zones of secondary lymphoid organs, where they present processed peptides to CD4+ helper T cells via MHC II. Cognate recognition by activated (Tfh) delivers essential co-stimulatory signals to the B cell, primarily through the interaction of CD40 ligand (CD40L) on the T cell with CD40 on the B cell, which promotes B cell proliferation and . Additionally, cytokines secreted by Tfh cells, such as IL-4, IL-21, and IFN-γ, further modulate B cell responses by enhancing proliferation and directing differentiation. This interaction facilitates the formation of germinal centers, where B cells undergo clonal expansion, , and affinity maturation. T-independent activation occurs without T cell involvement and is typically triggered by multivalent antigens, such as bacterial , that extensively BCRs due to their repetitive epitopes. These antigens often engage additional innate receptors, including Toll-like receptors (TLRs) on B cells, providing co-stimulatory signals that amplify BCR-mediated activation and promote rapid differentiation into short-lived plasma cells. Marginal zone and B1 B cells are particularly responsive to such stimuli, enabling quick IgM production against blood-borne pathogens. Upon activation through either pathway, B cells differentiate into antibody-secreting plasma cells or memory B cells, with the former requiring transcription factors like Blimp-1 and XBP-1 to suppress proliferation and upregulate secretory machinery. In T-dependent responses, this differentiation is more robust and leads to long-lived plasma cells that reside in the , while T-independent activation primarily yields short-lived effectors.

Antibody production and classes

Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins produced by plasma cells derived from activated B cells, consisting of two identical heavy chains and two identical light chains linked by bonds. The Y-shaped structure divides into the antigen-binding fragment (Fab) regions at the tips of the arms, which contain variable domains responsible for specific recognition, and the crystallizable fragment (Fc) region at the base, formed by constant domains that mediate interactions with immune cells and complement proteins. The variable domains in the Fab regions exhibit hypervariability in three complementarity-determining regions (CDRs) that form the antigen-binding site, while the constant domains determine the antibody's effector functions and isotype. Antibodies exist in five main isotypes in humans—Igm, IgG, IgA, IgE, and IgD—each defined by distinct constant regions of the heavy chain that confer unique structural and functional properties. IgM is the first isotype produced during an initial , existing primarily as a pentamer with high for multivalent antigens, while IgG predominates in secondary responses as a with strong tissue penetration. IgA functions mainly in mucosal immunity as a dimer, IgE mediates allergic responses and anti-parasitic defense, and IgD's role remains less defined but involves regulation. Class switching, or isotype switching, allows to change from producing IgM (and IgD) to IgG, IgA, or IgE without altering the variable region, enabling tailored immune responses; this process is mediated by activation-induced cytidine deaminase (AID), which initiates DNA double-strand breaks in switch regions upstream of constant region genes, followed by repair. Cytokines from T helper cells, such as IL-4 for IgE switching or IFN-γ for IgG subclasses, direct the choice of isotype during reactions. The effector functions of antibodies primarily occur via the Fc region and include neutralization, where antibodies bind pathogens to block their attachment to host cells; opsonization, which coats antigens to enhance by macrophages and neutrophils via Fc receptors; complement activation, initiating the classical pathway to form membrane attack complexes that lyse pathogens; and (ADCC), recruiting natural killer cells to destroy antibody-coated targets through Fcγ receptors. These functions vary by isotype: IgG subclasses excel in opsonization and ADCC, IgM is potent for complement activation due to its pentameric form, and IgA promotes mucosal opsonization but weakly activates complement. Neutralization and opsonization can occur independently of effector cells, providing rapid defense, while ADCC and complement activation amplify cellular and innate responses. Affinity maturation refines antibody specificity and strength during an through (SHM) and in germinal centers. SHM, also driven by , introduces point mutations at a high rate (about 10^{-3} per per generation) into the variable region genes of immunoglobulin loci, generating diversity in the CDRs. B cells with mutations yielding higher-affinity antibodies receive survival signals from presented on and T follicular helper cells, leading to selection and proliferation, while lower-affinity clones undergo ; this iterative process can increase affinity by 10- to 100-fold over days to weeks. Affinity maturation thus ensures robust, pathogen-specific .
IsotypeStructureKey Functions
IgMPentamer (or hexamer)Initial response; strong complement activation;
IgG (subclasses: IgG1-4)Opsonization; ADCC; neutralization; long-term immunity
IgADimer (secretory form)Mucosal immunity; opsonization in secretions
IgE; anti-parasitic; degranulation
IgDB cell surface receptor; unclear soluble role

Immunological Memory

Active immunity

Active immunity refers to the adaptive immune system's endogenous production of immunological following direct exposure to antigens, typically through natural , which confers long-term protection against subsequent encounters with the same . This process begins with the primary , where naive T and B lymphocytes recognize and respond to the for the first time, leading to a relatively slow phase that peaks after 7–10 days. During this phase, antigen-specific effector T cells and B cells proliferate, differentiate into short-lived effectors that eliminate the , and generate long-lived memory cells, establishing the foundation for future defenses. Upon re-exposure to the same , the secondary immune response, also known as the anamnestic response, is triggered by these memory cells, resulting in a faster onset (within 1–3 days) and greater magnitude compared to the primary response, with higher antibody titers and enhanced effector functions. This accelerated and amplified reaction effectively controls or prevents , highlighting the adaptive immune system's ability to "remember" prior threats. Memory T and B cells play pivotal roles here, rapidly expanding to produce antibodies and coordinate cellular immunity without the need for extensive naive cell recruitment. Memory cell formation occurs during the resolution of the primary response, where a subset of activated T and B cells survives and differentiates into distinct memory populations rather than undergoing . For T cells, central T cells (T_CM) primarily reside in secondary lymphoid organs, exhibit high proliferative potential, and maintain long-term surveillance, while effector T cells (T_EM) patrol peripheral tissues, providing immediate effector functions like production upon re-encounter. Similarly, memory B cells (MBCs) include central memory types in lymphoid tissues that undergo rapid class-switched antibody production and effector memory variants in mucosal or peripheral sites for swift local responses. These subsets ensure compartmentalized, efficient recall immunity tailored to the site's needs. The duration of active immunity varies by but can persist for decades or a lifetime, though it may wane over time due to cell attrition, necessitating periodic boosting through re-exposure to sustain . For instance, natural infection induces lifelong immunity, as evidenced by adults with a history of during childhood not acquiring after re-exposure 65 years later. This enduring underscores the potency of endogenous formation in preventing severe recurrence.

Passive immunity

Passive immunity refers to the transfer of pre-formed antibodies from an external source to provide immediate but temporary protection against pathogens, without stimulating the recipient's own or generating . This form of immunity relies on the recipient's absorption of exogenous antibodies, primarily (IgG) and (IgA), which neutralize pathogens or mark them for destruction by other immune components. Unlike adaptive responses that involve clonal expansion, passive immunity offers rapid onset but wanes as the transferred antibodies degrade. Natural passive immunity occurs primarily through maternal antibody transfer to the or newborn, as the adaptive immune system is immature at birth with suboptimal T- and B-cell responses and limited capacity for long-term memory formation, leaving infants vulnerable to infections not covered by these antibodies. During , IgG antibodies cross the placental barrier via the neonatal , providing the with protection against infections and during the early months of life. After birth, delivers IgA antibodies concentrated in and mature milk, which coat the infant's mucosal surfaces in the gastrointestinal and respiratory tracts to prevent adhesion and invasion; this passive protection is supplemented by vaccinations that stimulate the developing adaptive immune system. Artificial passive immunity involves the deliberate administration of antibodies, such as derived from immunized animals or s, or purified monoclonal antibodies, to confer immediate protection. For example, , often a combination of human or equine antibodies, is administered post-exposure alongside to neutralize the virus before it reaches the . Monoclonal antibodies, engineered for specificity, are increasingly used in targeted therapies, offering precise neutralization without the risks of polyclonal sera like . The duration of passive immunity is limited by the half-life of the transferred antibodies, typically lasting weeks to months. IgG antibodies have an average serum half-life of about 21 days, leading to gradual decline in protection until levels fall below effective thresholds, usually within 3 to 4 months. This short-lived nature makes suitable for bridging gaps in susceptibility rather than long-term defense. is particularly valuable for immediate protection in immunodeficient individuals, such as those with primary immunodeficiencies or undergoing immunosuppressive therapies, who cannot mount adequate responses to vaccines or infections. Antibody products like immune globulins provide a critical buffer against opportunistic pathogens during high-risk periods, such as post-transplant recovery or .

Immunization strategies

Immunization strategies represent artificial approaches to eliciting active immunity, leveraging the adaptive immune system's ability to generate long-term protection against pathogens through targeted exposure. These methods primarily involve , which introduce antigens in controlled forms to stimulate T cell and B cell responses without causing disease, thereby priming immunological memory for future encounters. By mimicking natural while minimizing risks, immunization has eradicated or controlled numerous infectious diseases globally. The foundation of modern traces back to Edward Jenner's 1796 development of the , the first successful vaccine in history, which used material from lesions to protect against the related variola virus; this breakthrough demonstrated the principle of cross-protective immunity and led to smallpox's global eradication in 1980. In the 20th and 21st centuries, vaccine innovation accelerated, with notable examples including the by in 1955 and the rapid deployment of mRNA-based COVID-19 vaccines in 2020, which encoded the to induce robust neutralizing production and were authorized for emergency use after demonstrating over 90% in phase 3 trials. These milestones highlight how strategies have evolved from empirical observations to sophisticated biotechnological interventions. Various vaccine types employ distinct mechanisms to present antigens and activate adaptive immunity. Live attenuated vaccines, such as those for , , and (MMR), use weakened s that replicate mildly in the host to provoke a strong, broad mimicking natural , conferring lifelong immunity in most recipients but contraindicated in immunocompromised individuals. Inactivated vaccines, like the inactivated polio vaccine (IPV), employ killed s or toxins to safely deliver antigens, stimulating primarily through production, though they may require boosters for sustained protection. Subunit vaccines, exemplified by the , isolate specific proteins (e.g., surface antigens) to target immune recognition without viral replication, offering precise and safe induction of B cell responses. mRNA vaccines, as in the Pfizer-BioNTech and COVID-19 formulations, deliver synthetic mRNA encoding antigens that cells translate into proteins, triggering both T cell and responses; their transient nature enhances safety and enables rapid adaptation to new variants. Viral vector vaccines, such as the COVID-19 vaccine using a modified adenovirus, ferry genes into host cells to produce antigens, eliciting cellular and while avoiding pre-existing immunity to common vectors. Achieving population-level protection often requires , where coverage reduces transmission to safeguard unvaccinated individuals; thresholds vary by , typically 80-95% for highly transmissible diseases like , as calculated from the (R0). Booster schedules reinforce waning immunity, such as annual vaccinations to counter antigenic drift or multiple doses in HPV programs to ensure durable protection against oncogenic strains, with ongoing 2025 initiatives expanding access in low-resource settings through WHO's Agenda 2030. Despite these advances, challenges persist, including driven by , which contributed to resurgence in several countries by 2023, and the need to update formulations against evolving variants, as seen in biennial COVID-19 booster recommendations targeting subvariants like JN.1 through 2025. Ongoing flu and HPV immunization programs face logistical hurdles in equitable distribution, yet demonstrate sustained impact, with HPV vaccination reducing incidence by up to 90% in vaccinated cohorts since introduction in 2006.

Generating Diversity

Genetic mechanisms

The adaptive immune system's capacity to recognize a vast array of antigens relies on germline-encoded genetic mechanisms that generate diversity in T cell receptors (TCRs) and B cell receptors (BCRs), also known as immunoglobulins, prior to any antigen encounter. These mechanisms primarily involve the rearrangement of gene segments within multigene families, ensuring a repertoire of receptors capable of binding diverse pathogens. Unlike the fixed, evolutionarily encoded receptors of the innate immune system, such as Toll-like receptors (TLRs), which recognize conserved pathogen-associated molecular patterns through limited germline variations, the adaptive system's genetic strategies enable combinatorial and junctional diversity on a massive scale. Central to this process is V(D)J recombination, a site-specific DNA rearrangement that assembles variable (V), diversity (D), and joining (J) gene segments to form functional receptor genes in developing lymphocytes. This recombination is mediated by the recombination-activating gene (RAG) proteins, RAG1 and RAG2, which form a complex that recognizes recombination signal sequences (RSSs) flanking the V, D, and J segments and introduces double-strand breaks at these sites. The broken DNA ends are then processed and ligated by the non-homologous end joining (NHEJ) pathway, resulting in the coding joint that encodes the variable region of the receptor and a signal joint that is discarded. For BCRs, V(D)J recombination occurs in the heavy chain locus (using V, D, and J segments) and light chain loci (using V and J segments only), while for TCRs, it involves similar segment usage, with D segments in the beta, delta, and gamma chains. The diversity generated by V(D)J recombination stems from two key features: combinatorial joining and junctional diversity. Combinatorial diversity arises from the random selection of one V, one or two D (where applicable), and one J segment from large multigene families; in humans, there are hundreds of such segments across the loci, including approximately 40-50 functional V segments, 25 D segments, and 6 J segments in the locus, with comparable scales in TCR loci. Junctional diversity further amplifies this by introducing variability at the segment junctions through the addition or removal of nucleotides by enzymes like (TdT), which adds non-templated N-nucleotides, and the imprecise processing of DNA ends. Together, these mechanisms can theoretically generate over 10^12 unique receptor specificities in humans, far exceeding the diversity possible from innate pattern recognition genes, which are encoded by fewer than 100 TLR family members recognizing broad microbial motifs. To maintain monospecificity, ensuring each expresses a single receptor specificity, regulates the recombination process such that only one of each receptor locus is productively rearranged per cell. This is achieved through a feedback mechanism where a functional protein product from the first successful rearrangement signals the inhibition of further recombination on the homologous , primarily via signaling pathways that enforce asynchronous replication timing and epigenetic silencing of the unrearranged locus. applies to both heavy and light chains in B cells and chains in T cells, preventing dual specificities that could lead to autoreactivity or inefficient responses. In contrast to the innate system's polyclonal activation via genes, this exclusion underpins the principle of adaptive immunity.

Somatic processes

Somatic hypermutation (SHM) is an antigen-driven process that introduces point mutations into the variable regions of immunoglobulin genes in activated B cells, primarily targeting the complementarity-determining regions (CDRs) to enhance antibody diversity and affinity. This process is initiated by the enzyme activation-induced cytidine deaminase (AID), which deaminates cytosine residues to uracil in single-stranded DNA during transcription, leading to a mutation rate of approximately 10^{-3} to 10^{-4} mutations per base pair per cell division—orders of magnitude higher than the spontaneous genomic mutation rate.00078-7) The resulting mismatches are processed by error-prone DNA repair pathways, such as base excision repair and mismatch repair, which incorporate mutations at both C/G and A/T pairs, thereby refining antibody specificity. Affinity maturation occurs concurrently with SHM in germinal centers of secondary lymphoid organs, where B cells proliferate and compete for antigen presented on follicular dendritic cells and T follicular helper cells. High-affinity B cell clones are positively selected through interactions that promote survival signals, while low-affinity clones undergo apoptosis, resulting in a progressive increase in average antibody affinity by 10- to 100-fold over the course of an immune response. This Darwinian selection process ensures that the humoral response evolves toward higher-affinity antibodies capable of more effective pathogen neutralization. In mammals, this refinement is almost exclusively driven by SHM, distinguishing it from the initial V(D)J recombination that establishes baseline diversity. In some non-mammalian , such as chickens, somatic diversification also involves gene conversion, where segments from upstream pseudogenes are copied into the functional variable region , introducing blocks of to expand diversity.90311-0) plays a central role here as well, facilitating the homologous recombination events that replace portions of the rearranged V with sequences from a library of pseudogenes, achieving diversification rates comparable to SHM in mammals. This mechanism predominates in avian B cells within the and contributes to broad coverage without relying heavily on junctional diversity. These somatic processes collectively broaden the adaptive immune response to accommodate evolving pathogens, such as viral variants, by generating antibodies with enhanced and potency through iterative and selection. For instance, SHM enables the adaptation of SARS-CoV-2-specific antibodies to emerging variants by introducing bystander mutations that improve binding to conserved epitopes.00485-5) This dynamic refinement is crucial for long-term protective immunity against pathogens that undergo rapid antigenic drift.

Regulation

Immune tolerance

Immune tolerance encompasses the adaptive immune system's mechanisms to discriminate self from non-self, preventing autoreactive responses that could lead to autoimmunity. These processes ensure that lymphocytes reactive to self-antigens are either eliminated or rendered inactive, maintaining immune homeostasis. Central tolerance operates during lymphocyte maturation in primary lymphoid organs, while peripheral tolerance provides backup suppression in mature cells that escape central checkpoints. Central tolerance for T cells occurs primarily in the through negative selection, where developing thymocytes with T cell receptors (TCRs) exhibiting high affinity for self-peptide-major histocompatibility complex (MHC) ligands undergo . This deletion targets double-positive thymocytes in the cortex for ubiquitous antigens and single-positive cells in the medulla for tissue-specific antigens, presented by medullary thymic epithelial cells (mTECs) and dendritic cells. The process relies on proapoptotic molecules like Bim and Nur77 to induce the intrinsic pathway, eliminating up to 95% of thymocytes. For B cells, central tolerance takes place in the at the immature IgM+ stage, where B cell receptors (BCRs) binding self-antigens trigger checkpoints: receptor editing, involving secondary light-chain gene rearrangement to alter specificity (occurring in 20-35% of autoreactive cells), or via Bim-mediated pathways if editing fails. This reduces autoreactive B cells from 50-75% in early to about 10-40% in the mature repertoire. A key facilitator of central T cell tolerance is the autoimmune regulator (AIRE) gene, expressed in mTECs, which transcriptionally activates of thousands of tissue-restricted self-, such as insulin and . AIRE binds to unmethylated H3K4 marks, promoting stochastic TSA to just 1-2% of mTECs per , enabling effective negative selection of organ-specific autoreactive T cells. Defects in AIRE, as seen in Aire-knockout mice, impair this and lead to multi-organ , underscoring its role. Peripheral tolerance mechanisms act on autoreactive lymphocytes that evade central deletion, including anergy, where T cells encountering self-antigens without costimulatory signals (e.g., ligation) become hyporesponsive, upregulating inhibitory molecules like CTLA-4 and PD-1 while inhibiting and production. Deletion eliminates these cells via Fas- or Bim-dependent in secondary lymphoid organs, often induced by tolerogenic dendritic cells or stromal cells. Regulatory T cells (Tregs), primarily + + cells derived from the or periphery, suppress autoreactivity through direct contact, secretion (e.g., IL-10, TGF-β, IL-35), and metabolic disruption of effector T cells, maintaining balance in tissues. The discovery of these + Tregs and their role in peripheral tolerance by Shimon Sakaguchi, Mary Brunkow, and Fred Ramsdell was awarded the 2025 in or . Breakdowns in immune tolerance contribute to autoimmune diseases; for example, in , central failures such as reduced thymic insulin expression due to INS gene polymorphisms allow escape of β-cell-specific autoreactive T cells, while peripheral defects like impaired Treg function from low IL-2 signaling and reduced inhibitory receptor expression (e.g., CTLA-4, PD-1) enable their activation and pancreatic infiltration. These combined lapses result in progressive β-cell destruction, highlighting tolerance as a multi-layered safeguard.

Immune network hypothesis

The immune network hypothesis, also known as the idiotypic , was proposed by Niels Kaj Jerne in 1974 as a framework for understanding the self-regulation of the adaptive immune system. In this model, the variable regions of antibodies and T-cell receptors—termed idiotypes—act not only as recognition sites for foreign antigens but also as antigens themselves, recognized by complementary anti-idiotypic immune components. This mutual recognition creates an interconnected network where an initial antibody response (Ab1) to an antigen elicits anti-idiotypic antibodies (Ab2) that bind to Ab1's idiotype, potentially suppressing or modulating the response; Ab2 can then stimulate further anti-anti-idiotypic antibodies (Ab3), forming a dynamic cascade that maintains without constant external antigenic stimulation. The theory has implications for stimulating adaptive immunity, particularly through anti-idiotype vaccines, where Ab2 mimics the three-dimensional structure of a pathogen's to elicit a targeted akin to the original . For instance, anti-idiotypic antibodies have been used experimentally to induce protective immunity against tumors and viruses by engaging the network to amplify specific B- and T-cell clones. In the context of , network suppression occurs when anti-idiotypic interactions dampen autoreactive responses, preventing excessive activation and contributing to the balance between immunity and self-tolerance. Post-2000 refinements have integrated the idiotypic network with advances in regulatory T cells (Tregs) and cytokines, proposing that anti-idiotypic Tregs suppress effector responses via network interactions, while cytokines like IL-10 and TGF-β modulate network connectivity to fine-tune . This updated view posits the network as a layered system where Tregs bearing anti-idiotypic specificities enforce , bridging classical network dynamics with contemporary . Despite its foundational influence, the has drawn criticisms for assuming an overly connected network given the vast diversity of the immune , which may limit the feasibility of widespread idiotypic interactions, and for lacking predictive power in complex scenarios, rendering it largely of historical interest today. However, evidence from autoimmune models supports its relevance; for example, in experimental autoimmune encephalomyelitis, anti-idiotypic antibodies targeting pathogenic clones reduce disease severity by network-mediated suppression, and similar interactions modulate progression.

Acquired immunity during pregnancy

During pregnancy, the adaptive immune system undergoes specific modifications to accommodate the semi-allogeneic , balancing protection against pathogens with prevention of maternal rejection. These adaptations include shifts in T cell subsets and antibody dynamics that promote fetal tolerance while maintaining maternal immune competence. A key mechanism for fetal tolerance involves the expansion of regulatory T cells (Tregs), which suppress pro-inflammatory responses at the maternal-fetal interface. Tregs increase in number and function early in , peaking in the first and second trimesters, to inhibit effector T cell activity and promote an anti-inflammatory environment. Concurrently, there is a shift toward Th2 dominance, characterized by elevated levels of interleukin-4, -10, and -13, which favor and dampen Th1-mediated that could harm the fetus. This Th2 bias, alongside Treg activity, ensures immune and supports placental development. Maternal antibody transfer provides to the , primarily through the transplacental passage of (IgG). This process is mediated by the neonatal (FcRn) expressed on cells in the , which binds IgG in maternal circulation and facilitates its transport to the fetal compartment in a pH-dependent manner. IgG transfer increases exponentially from the second trimester onward, peaking near term, and equips the neonate with protective antibodies against infections until its own adaptive immunity matures. Disruptions in these adaptive mechanisms can lead to pathological conditions such as , where failure of Treg-mediated tolerance and excessive Th1/Th17 responses contribute to placental and vascular dysfunction. In , reduced Treg numbers and impaired balance result in endothelial damage and systemic immune dysregulation, often preceding clinical symptoms like . Gestational , manifesting as exacerbated autoimmune responses or de novo flares during , similarly arises from breakdowns in adaptive tolerance, increasing risks for conditions like remission failure or with immune components. Postpartum, the adaptive immune system undergoes restoration, reverting from Th2 dominance to a balanced Th1/Th2 profile within weeks to months, with Treg levels declining to pre-pregnancy baselines. This recovery supports maternal defense against infections but can unmask latent . Breastfeeding aids this process by sustaining elevated and oxytocin levels, which modulate immune cell activity and enhance production in , indirectly supporting maternal immune while providing the with secretory IgA and other adaptive factors.

Evolution and Variations

Evolutionary origins

The adaptive immune system first emerged in jawed vertebrates, or gnathostomes, approximately 500 million years ago during the period, marking a pivotal innovation in vertebrate . This development coincided with the divergence from jawless vertebrates, such as lampreys and , and was facilitated by the acquisition of recombination-activating genes ( and RAG2), which originated from an ancient transposon. Concurrently, the (MHC) evolved to enable , allowing T cells to recognize foreign peptides in a self-restricted manner. These genetic elements provided the foundation for specific, memory-based immune responses absent in more primitive chordates. Central to this system's phylogeny were key innovations like V(D)J recombination, a somatic process that assembles variable (V), diversity (D), and joining (J) gene segments to generate diverse antigen receptors. This mechanism underpins the immunoglobulin (Ig) and T cell receptor (TCR) superfamily, whose members share structural domains and function in B and T lymphocyte recognition across all jawed vertebrates. The Ig/TCR superfamily diversified early, with evidence of both αβ and γδ TCR variants in basal gnathostomes, reflecting an ancient split that enhanced pathogen surveillance. The evolution of the adaptive immune system was driven by co-evolution with pathogens, exerting selective pressures that favored increased receptor diversity and affinity maturation. In early vertebrates, exposure to diverse microbial threats likely accelerated the refinement of RAG-mediated recombination and MHC polymorphism, as seen in the high variability of MHC loci in primitive fish species. This contributed to the system's robustness, enabling vertebrates to counter evolving infectious agents more effectively than innate defenses alone. Fossil and genetic evidence traces this system's progression from early gnathostomes to mammals. Phylogenetic analyses place its origin near the Cambrian-Ordovician boundary, inferred from the ~500-million-year-old divergence of chondrichthyans (), which possess functional Ig and TCR genes organized in clusters. In bony fish, such as , genomic sequencing reveals conserved V(D)J machinery and lymphoid organs, bridging to tetrapods. By the period (~400 million years ago), amphibians and subsequent amniotes (reptiles, birds, mammals) show elaborated structures like lymph nodes, underscoring a continuous refinement without major discontinuities.

Adaptive-like systems in other species

In jawless vertebrates such as lampreys and , an adaptive immune system analogous to that in jawed vertebrates operates through variable lymphocyte receptors (VLRs), which are somatically diversified to recognize antigens. Unlike the recombination-based immunoglobulin and systems in jawed vertebrates, VLRs achieve diversity via a gene conversion-like process involving the assembly of variable segments from flanking modules onto incomplete germ-line VLR s in s. This mechanism generates a vast repertoire of VLRs expressed on the surface of distinct lineages, enabling antigen-specific responses and immunological memory without the involvement of RAG-mediated recombination. In like , adaptive-like immune responses lack lymphocytes but incorporate sequence-specific mechanisms such as (RNAi) for antiviral defense. In , RNAi is triggered by viral double-stranded RNA, which is processed into small interfering RNAs (siRNAs) by Dicer-2; these siRNAs then guide Argonaute-2 to cleave complementary viral RNA, providing a targeted, heritable suppression of specific pathogens. Circulating hemocytes amplify and disseminate these siRNAs systemically, conferring a form of immunological memory that enhances resistance to reinfection. The phenoloxidase system complements this by activating melanization cascades in response to pathogens, though it operates more broadly through receptors rather than sequence specificity. Bacteria employ CRISPR-Cas systems as a form of adaptive antiviral immunity, acquiring short DNA sequences (spacers) from invading phages or plasmids and integrating them into CRISPR arrays to create heritable memory. Upon reinfection, CRISPR transcripts form RNA guides that direct Cas nucleases to cleave matching foreign DNA with high specificity, preventing viral replication while sparing self-genomes through protospacer-adjacent motif recognition. These adaptive-like systems in non-vertebrates illustrate of antigen-specific recognition and memory, distinct from the lymphocyte-based architecture in jawed vertebrates, and highlight the modular origins of adaptive immunity across kingdoms. By comparing VLRs, RNAi, and CRISPR-Cas to vertebrate mechanisms, researchers gain insights into the selective pressures driving immune innovation, underscoring the uniqueness of RAG-dependent recombination in enabling scalable, dual B- and T-cell responses in jawed vertebrates.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.